Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Stopped early · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

In brief

The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Key facts

Study ID

NCT00234481

Run by

Exelixis

Last updated by the study team

2008-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
• Prior treatment with at least 2 systemic chemotherapy regimens for CLL
• Life expectancy of >3 months
• Adequate liver and kidney function
• Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

You may not qualify if…

• Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Investigational drug within 30 days of the start of treatment
• Uncontrolled intercurrent illness such as infection or cardiovascular disease
• Pregnant or breastfeeding women
• Subjects known to be HIV positive

Where it is running

• City of Hope National Cancer Center — Duarte, California, United States
• UCSD Moores Cancer Center — San Diego, California, United States
• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.